Result of AGM

/**/

RNS Number : 0266N SkinBioTherapeutics PLC 29 December 2025  

  SkinBioTherapeutics plc ("SkinBioTherapeutics" or "the Group")   Result of Annual General Meeting   29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.  

Resolution

Votes For

Votes Against

Votes Withheld

1. To receive the annual report and accounts

88,024,558

83.50%

17,391,981

16.50%

722,198

2. To re-appoint Gravita as auditor

96,998,314

92.15%

8,266,920

7.85%

873,503

3. To authorise Directors to determine Auditors renumeration

97,093,358

92.13%

8,296,876

7.87%

748,503

4. To authorise the Directors to allot relevant securities

85,828,638

80.90%

20,268,099

19.10%

42,000

5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders

85,771,888

80.84%

20,324,849

19.16%

 42,000

6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment

85,782,499

81.34%

19,682,546

18.66%

673,692

  An electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations.   -Ends-   For more information please contact:  

SkinBioTherapeutics plc Stuart J. Ashman, CEO Emily Bertram, Group Finance Director

+44 (0) 191 495 7325  

Singer Capital Markets (Nominated Adviser & Broker) Philip Davies Andrew Johnson James Todd

+44 (0) 020 7496 3000  

Vigo Consulting (financial press) Rozi Morris, Melanie Toyne-Sewell

+44 (0) 20 7390 0230 SkinBio@vigoconsulting.com 

  Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores. The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.  The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  RAGPKCBBNBDDPBB